Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

RNA Regulators in Leukemia and Lymphoma.

Prieto C, Kharas MG.

Cold Spring Harb Perspect Med. 2019 Oct 15. pii: a034967. doi: 10.1101/cshperspect.a034967. [Epub ahead of print]

PMID:
31615866
2.

m6A RNA Methylation Maintains Hematopoietic Stem Cell Identity and Symmetric Commitment.

Cheng Y, Luo H, Izzo F, Pickering BF, Nguyen D, Myers R, Schurer A, Gourkanti S, Brüning JC, Vu LP, Jaffrey SR, Landau DA, Kharas MG.

Cell Rep. 2019 Aug 13;28(7):1703-1716.e6. doi: 10.1016/j.celrep.2019.07.032.

3.

Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.

Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, Gavrila EI, Stewart C, Melnik EM, Herrejon Chavez F, Bitner L, Yoshimi A, Lee SC, Inoue D, Liu B, Zhang XJ, Mato AR, Dogan A, Kharas MG, Chen Y, Wang D, Soni RK, Hendrickson RC, Prieto G, Rodriguez JA, Taylor BS, Abdel-Wahab O.

Cancer Discov. 2019 Oct;9(10):1452-1467. doi: 10.1158/2159-8290.CD-19-0298. Epub 2019 Jul 8.

PMID:
31285298
4.

Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia.

Minuesa G, Albanese SK, Xie W, Kazansky Y, Worroll D, Chow A, Schurer A, Park SM, Rotsides CZ, Taggart J, Rizzi A, Naden LN, Chou T, Gourkanti S, Cappel D, Passarelli MC, Fairchild L, Adura C, Glickman JF, Schulman J, Famulare C, Patel M, Eibl JK, Ross GM, Bhattacharya S, Tan DS, Leslie CS, Beuming T, Patel DJ, Goldgur Y, Chodera JD, Kharas MG.

Nat Commun. 2019 Jun 19;10(1):2691. doi: 10.1038/s41467-019-10523-3.

5.

The Biology of m6A RNA Methylation in Normal and Malignant Hematopoiesis.

Vu LP, Cheng Y, Kharas MG.

Cancer Discov. 2019 Jan;9(1):25-33. doi: 10.1158/2159-8290.CD-18-0959. Epub 2018 Dec 21. Review.

PMID:
30578356
6.

IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation.

Park SM, Cho H, Thornton AM, Barlowe TS, Chou T, Chhangawala S, Fairchild L, Taggart J, Chow A, Schurer A, Gruet A, Witkin MD, Kim JH, Shevach EM, Krivtsov A, Armstrong SA, Leslie C, Kharas MG.

Cell Stem Cell. 2019 Jan 3;24(1):153-165.e7. doi: 10.1016/j.stem.2018.10.016. Epub 2018 Nov 21.

PMID:
30472158
7.

Targeting the Residual Leukemia Cells after Chemotherapy.

Vu LP, Kharas MG.

Cancer Cell. 2018 Sep 10;34(3):353-355. doi: 10.1016/j.ccell.2018.08.012.

8.

Dual Strategies for Argonaute2-Mediated Biogenesis of Erythroid miRNAs Underlie Conserved Requirements for Slicing in Mammals.

Jee D, Yang JS, Park SM, Farmer DT, Wen J, Chou T, Chow A, McManus MT, Kharas MG, Lai EC.

Mol Cell. 2018 Jan 18;69(2):265-278.e6. doi: 10.1016/j.molcel.2017.12.027.

9.

Peptidomimetic blockade of MYB in acute myeloid leukemia.

Ramaswamy K, Forbes L, Minuesa G, Gindin T, Brown F, Kharas MG, Krivtsov AV, Armstrong SA, Still E, de Stanchina E, Knoechel B, Koche R, Kentsis A.

Nat Commun. 2018 Jan 9;9(1):110. doi: 10.1038/s41467-017-02618-6.

10.

The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.

Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, Schulman J, Famulare C, Patel M, Klimek VM, Garrett-Bakelman FE, Melnick A, Carroll M, Mason CE, Jaffrey SR, Kharas MG.

Nat Med. 2017 Nov;23(11):1369-1376. doi: 10.1038/nm.4416. Epub 2017 Sep 18.

11.

Stem Cells, Cancer, and MUSASHI in Blood and Guts.

Kharas MG, Lengner CJ.

Trends Cancer. 2017 May;3(5):347-356. doi: 10.1016/j.trecan.2017.03.007. Epub 2017 Apr 8. Review.

12.

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.

Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.

13.

Real-time quantitative analysis of metabolic flux in live cells using a hyperpolarized micromagnetic resonance spectrometer.

Jeong S, Eskandari R, Park SM, Alvarez J, Tee SS, Weissleder R, Kharas MG, Lee H, Keshari KR.

Sci Adv. 2017 Jun 16;3(6):e1700341. doi: 10.1126/sciadv.1700341. eCollection 2017 Jun.

14.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2017 Jun 1;127(6):2438. doi: 10.1172/JCI95182. Epub 2017 Jun 1. No abstract available.

15.

Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, Kwon JA, Meydan C, Perales-Paton J, Arshi A, Gönen M, Famulare C, Patel M, Paietta E, Tallman MS, Lu Y, Glass J, Garret-Bakelman FE, Melnick A, Levine R, Al-Shahrour F, Järås M, Hacohen N, Hwang A, Garippa R, Lengner CJ, Armstrong SA, Cerchietti L, Cowley GS, Root D, Doench J, Leslie C, Ebert BL, Kharas MG.

Nat Genet. 2017 Jun;49(6):866-875. doi: 10.1038/ng.3854. Epub 2017 Apr 24.

16.

Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Kotini AG, Chang CJ, Chow A, Yuan H, Ho TC, Wang T, Vora S, Solovyov A, Husser C, Olszewska M, Teruya-Feldstein J, Perumal D, Klimek VM, Spyridonidis A, Rampal RK, Silverman L, Reddy EP, Papaemmanuil E, Parekh S, Greenbaum BD, Leslie CS, Kharas MG, Papapetrou EP.

Cell Stem Cell. 2017 Mar 2;20(3):315-328.e7. doi: 10.1016/j.stem.2017.01.009. Epub 2017 Feb 16.

17.

Emerging links between m6A and misregulated mRNA methylation in cancer.

Jaffrey SR, Kharas MG.

Genome Med. 2017 Jan 12;9(1):2. doi: 10.1186/s13073-016-0395-8.

18.

Msi RNA-binding proteins control reserve intestinal stem cell quiescence.

Yousefi M, Li N, Nakauka-Ddamba A, Wang S, Davidow K, Schoenberger J, Yu Z, Jensen ST, Kharas MG, Lengner CJ.

J Cell Biol. 2016 Nov 7;215(3):401-413. Epub 2016 Oct 31.

19.

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.

Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, Nahas MK, He J, Hadler M, Stein EM, Tallman MS, Donahue AL, Frampton GM, Lipson D, Roels S, Stephens PJ, Sanford EM, Brennan T, Otto GA, Yelensky R, Miller VA, Kharas MG, Levine RL, Ferrando A, Armstrong SA, Krivtsov AV.

Leukemia. 2017 Jan;31(1):151-158. doi: 10.1038/leu.2016.166. Epub 2016 Jun 13.

20.

MUSASHI-2 duels in myelodysplastic syndromes.

Ho TC, Taggart J, Kharas MG.

Cell Cycle. 2016 Jul 17;15(14):1799-800. doi: 10.1080/15384101.2016.1176401. Epub 2016 Apr 22. No abstract available.

21.

MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.

Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG.

Nat Commun. 2016 Feb 22;7:10739. doi: 10.1038/ncomms10739.

22.

The Msi Family of RNA-Binding Proteins Function Redundantly as Intestinal Oncoproteins.

Li N, Yousefi M, Nakauka-Ddamba A, Li F, Vandivier L, Parada K, Woo DH, Wang S, Naqvi AS, Rao S, Tobias J, Cedeno RJ, Minuesa G, Y K, Barlowe TS, Valvezan A, Shankar S, Deering RP, Klein PS, Jensen ST, Kharas MG, Gregory BD, Yu Z, Lengner CJ.

Cell Rep. 2015 Dec 22;13(11):2440-2455. doi: 10.1016/j.celrep.2015.11.022. Epub 2015 Dec 8.

23.

Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles.

Hatlen MA, Arora K, Vacic V, Grabowska EA, Liao W, Riley-Gillis B, Oschwald DM, Wang L, Joergens JE, Shih AH, Rapaport F, Gu S, Voza F, Asai T, Neel BG, Kharas MG, Gonen M, Levine RL, Nimer SD.

J Exp Med. 2016 Jan 11;213(1):25-34. doi: 10.1084/jem.20150524. Epub 2015 Dec 14.

24.

Transformation of the intestinal epithelium by the MSI2 RNA-binding protein.

Wang S, Li N, Yousefi M, Nakauka-Ddamba A, Li F, Parada K, Rao S, Minuesa G, Katz Y, Gregory BD, Kharas MG, Yu Z, Lengner CJ.

Nat Commun. 2015 Mar 16;6:6517. doi: 10.1038/ncomms7517.

25.

Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, Levine R, Leslie C, Lengner CJ, Kharas MG.

J Clin Invest. 2015 Mar 2;125(3):1286-98. doi: 10.1172/JCI78440. Epub 2015 Feb 9.

26.

The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.

Gustafsson K, Jamalpour M, Trinh C, Kharas MG, Welsh M.

J Hematol Oncol. 2014 Jun 21;7:45. doi: 10.1186/1756-8722-7-45.

27.

A 1536-well fluorescence polarization assay to screen for modulators of the MUSASHI family of RNA-binding proteins.

Minuesa G, Antczak C, Shum D, Radu C, Bhinder B, Li Y, Djaballah H, Kharas MG.

Comb Chem High Throughput Screen. 2014;17(7):596-609.

28.

Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.

Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, Scheinberg DA.

Clin Cancer Res. 2014 Aug 1;20(15):4036-46. doi: 10.1158/1078-0432.CCR-13-2756. Epub 2014 May 21.

29.

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.

Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL.

J Exp Med. 2014 Apr 7;211(4):605-12. doi: 10.1084/jem.20131033. Epub 2014 Mar 10.

30.

Musashi-2 controls cell fate, lineage bias, and TGF-β signaling in HSCs.

Park SM, Deering RP, Lu Y, Tivnan P, Lianoglou S, Al-Shahrour F, Ebert BL, Hacohen N, Leslie C, Daley GQ, Lengner CJ, Kharas MG.

J Exp Med. 2014 Jan 13;211(1):71-87. doi: 10.1084/jem.20130736. Epub 2014 Jan 6.

31.

In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.

Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, Scadden DT, Hynes RO, Mukherjee S, Stegmaier K, Jordan CT, Ebert BL.

Cancer Cell. 2013 Jul 8;24(1):45-58. doi: 10.1016/j.ccr.2013.05.004. Epub 2013 Jun 13.

32.

EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.

Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, Clary DO, Gilliland DG.

Leukemia. 2012 Apr;26(4):720-7. doi: 10.1038/leu.2011.261. Epub 2011 Oct 18.

PMID:
22005786
33.

The Lin28/let-7 axis regulates glucose metabolism.

Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG, Urbach A, Thornton JE, Triboulet R, Gregory RI; DIAGRAM Consortium; MAGIC Investigators, Altshuler D, Daley GQ.

Cell. 2011 Sep 30;147(1):81-94. doi: 10.1016/j.cell.2011.08.033.

34.

From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.

Kharas MG, Daley GQ.

Genes Cancer. 2010 Dec;1(12):1164-9. doi: 10.1177/1947601911407327.

35.

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.

Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Fröhling S, Fleming M, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ.

Nat Med. 2010 Aug;16(8):903-8. doi: 10.1038/nm.2187. Epub 2010 Jul 8.

36.

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.

Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.

37.

Akt: a double-edged sword for hematopoietic stem cells.

Kharas MG, Gritsman K.

Cell Cycle. 2010 Apr 1;9(7):1223-4. Epub 2010 Apr 1. No abstract available.

PMID:
20234178
38.

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K.

Blood. 2010 Feb 18;115(7):1406-15. doi: 10.1182/blood-2009-06-229443. Epub 2009 Dec 14.

39.

Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis.

Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG.

Cell Stem Cell. 2009 Jun 5;4(6):559-67. doi: 10.1016/j.stem.2009.03.016.

40.

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.

Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, Beylot-Barry M, Rodig SJ, Aster JC, Lee BH, Cantor H, Merlio JP, Gilliland DG, Mercher T.

Blood. 2009 Mar 19;113(12):2746-54. doi: 10.1182/blood-2008-06-164368. Epub 2009 Jan 12.

41.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2008 Sep;118(9):3038-50. doi: 10.1172/JCI33337. Erratum in: J Clin Invest. 2017 Jun 1;127(6):2438.

42.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG.

Cancer Cell. 2008 Apr;13(4):311-20. doi: 10.1016/j.ccr.2008.02.009.

43.

KLF4 is a FOXO target gene that suppresses B cell proliferation.

Yusuf I, Kharas MG, Chen J, Peralta RQ, Maruniak A, Sareen P, Yang VW, Kaestner KH, Fruman DA.

Int Immunol. 2008 May;20(5):671-81. doi: 10.1093/intimm/dxn024. Epub 2008 Mar 28.

PMID:
18375530
44.
45.

T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling.

Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA.

Blood. 2007 Apr 1;109(7):2894-902.

46.

Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase.

Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16882-7. Epub 2006 Oct 27. Erratum in: Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10871.

47.

KLF4 suppresses transformation of pre-B cells by ABL oncogenes.

Kharas MG, Yusuf I, Scarfone VM, Yang VW, Segre JA, Huettner CS, Fruman DA.

Blood. 2007 Jan 15;109(2):747-55. Epub 2006 Sep 5.

48.

S6 kinase 2 potentiates interleukin-3-driven cell proliferation.

Cruz R, Hedden L, Boyer D, Kharas MG, Fruman DA, Lee-Fruman KK.

J Leukoc Biol. 2005 Dec;78(6):1378-85. Epub 2005 Oct 4.

49.

ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.

Kharas MG, Fruman DA.

Cancer Res. 2005 Mar 15;65(6):2047-53. Review.

50.

Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors.

Yusuf I, Zhu X, Kharas MG, Chen J, Fruman DA.

Blood. 2004 Aug 1;104(3):784-7. Epub 2004 Apr 6.

PMID:
15069012

Supplemental Content

Loading ...
Support Center